Lewis Plachy, MD
Internal Medicine · Lincoln, NENPI 1083622450
Payments from drug & device makers
Across 72 payments — averaging $36.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$651
- Astellas Pharma US Inc$293
- Mylan Specialty L.p.$249
- Optinose US, Inc.$215
- Pfizer$197
- AstraZeneca$169
- plus $818 from 18 others
What the payments were for
- Food & beverage$2,42794%
- Education$1656%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 9 | $651 |
| Astellas Pharma US Inc | 4 | $293 |
| Mylan Specialty L.p. | 9 | $249 |
| Optinose US, Inc. | 8 | $215 |
| Pfizer | 8 | $197 |
| AstraZeneca | 3 | $169 |
| GSK | 3 | $157 |
| Novo Nordisk | 7 | $156 |
| Medtronic | 1 | $80 |
| AbbVie | 3 | $68 |
| Sanofi-aventis U.S. LLC | 1 | $61 |
| Viatris Specialty LLC | 2 | $54 |
| Eisai Inc. | 1 | $48 |
| Amgen | 2 | $28 |
| Sanofi Pasteur Inc. | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Bayer | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$101
How this compares
$2,592 in reported general payments places this provider in the 85th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 12 | $91,442 |
| EliquisApixaban | 113 | $84,477 |
| OzempicSemaglutide | 53 | $74,763 |
| XareltoRivaroxaban | 52 | $67,264 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $28,721 |
| TrulicityDulaglutide | 26 | $24,891 |
| JanuviaSitagliptin Phosphate | 32 | $24,441 |
| FarxigaDapagliflozin Propanediol | 24 | $16,494 |
| JardianceEmpagliflozin | 12 | $14,833 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $10,820 |
| MyrbetriqMirabegron | 20 | $9,965 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $8,232 |
| Ezetimibe | 163 | $7,031 |
| SynthroidLevothyroxine Sodium | 79 | $6,942 |
| GemtesaVibegron | 12 | $6,291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $197 | $84,477113 claims |
| Novo NordiskOzempic | $156 | $74,76353 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $651 | $31,84946 claims |
| Lilly USA, LLCTrulicity | $13 | $24,89126 claims |
| AstraZenecaFarxiga | $169 | $16,49424 claims |
| Astellas Pharma US IncMyrbetriq | $293 | $9,96520 claims |
| AbbVieSynthroid | $68 | $6,94279 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Lincoln
- Scott RasmussenLincoln$38.1M
- Alexander RyanLincoln$2.2M
- Jason PottsLincoln$686K
- Sherri ThomasLincoln$136K
- Aaron WardLincoln$40K
- Anthony RossLincoln$6K
- Wasim ChughtaiLincoln$6K
- Mary DreyLincoln$6K
- Charles HarperNorfolk$31.1M
- Robert SchwabBoys Town$9.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.